Shanghai Unibio Lab Co., Ltd., headquartered in Qingpu District, Shanghai, China, is a specialized biotechnology company dedicated to the research, production, and formulation of high-quality probiotics, postbiotics, and next-generation functional ingredients. As a science-driven enterprise with a strong global orientation, Unibio Lab integrates advanced fermentation technology with proprietary delivery systems to meet the growing demand for gut health, immunity, metabolic health, and personalized nutrition. ## Core Business and Product Portfolio Unibio Lab operates in the domains of clinical probiotics, microbiome innovation, and health-focused bioactives. The company’s product development is grounded in microbiota science, with a focus on human clinical relevance and precision-targeted formulations. ### Main Product Categories: - Probiotic Powders - Clinical Probiotics: Supported by published studies - Patented Strains: Developed through in-house research and global licensing - Generic Probiotics: Bifidobacterium, Lactobacillus, Streptococcus, etc. - Probiotic Blends: Custom strains based on indication - Probiotic Capsules - Finished dosage forms for private label clients - Enteric-coated delivery systems for high CFU viability - Postbiotics Powder - Proprietary ProLipo® postbiotics line - Metabolite-rich lysates for inflammation, immunity, and gut barrier support - Next-Generation Probiotics - Novel strains including: - Akkermansia muciniphila AH39 - Faecalibacterium prausnitzii - Products designed for metabolic and aging health applications - Enzyme Blends - Digestive enzymes tailored to work synergistically with probiotics ## Proprietary Brands - VPro® – Micro-encapsulated probiotic strains with proven stability - ProLipo® – Next-gen postbiotic powders targeting immune modulation - HelpGut® – Clinical formulations for GI health, women's health, and metabolic support ## Technological Capabilities Unibio Lab’s strength lies in its robust R&D pipeline, led by a team of microbiologists, fermentation experts, and nutrition scientists. Key technological platforms include: - Microencapsulation Technology: Ensures over 90% survival rate through gastric acid - Freeze-drying & Spray Drying: Maintains CFU integrity and shelf-life stability - Omics-based Screening: For precision probiotic selection and personalized blends - Patent-protected strains: Registered in both China and international patent offices Manufacturing complies with GMP, HACCP, and ISO 22000 standards and includes both bulk powder production and capsule filling lines. ## Production Capacity and Financial Performance While detailed financials are undisclosed, industry estimates and public data indicate: - Probiotic capacity: Over 800 metric tons annually - Encapsulation line output: Approx. 200 million capsules/year - Annual revenue: Estimated between USD 20–35 million - Export ratio: Around 65%, with rising demand from Europe and Southeast Asia ## Export Trade and Shipment Data Based on insights from ImportYeti, Volza, and B2B sources: - Major markets: United States, Germany, Australia, Japan, South Korea, UAE - Over 1,000 international shipments in the past five years - HS Codes used: - 21069099 – Food supplements - 300490 – Medicinal preparations containing microorganisms - 350790 – Enzyme preparations ## Target Markets and Industry Applications Unibio Lab serves a diverse client base in health and wellness industries: - Nutraceutical companies - Functional food & beverage manufacturers - Infant & maternal health brands - Sports nutrition companies - Clinical and pharmacy-grade supplement providers - Private-label OEM partners ## Certifications and Quality Systems Unibio Lab meets global compliance standards with the following certifications: - ISO 22000 – Food Safety Management System - HACCP Certified - GMP Compliant Facility - FDA Registered (for export) - Halal Certification - Kosher Certification - Patent Registrations – China, EU, and USA Each product batch is supported by: - Certificate of Analysis (COA) - Stability Data (ambient and cold chain) - CFU count and viability report - Microbiological safety profile ## Innovation, Clinical Validation & R&D The company is heavily invested in research, with collaborations across: - Shanghai Jiao Tong University School of Medicine - Chinese Academy of Sciences - National Microbiome Research Program Areas of active R&D: - Probiotics for obesity, diabetes, IBS, IBD - Postbiotic metabolites for immune and neurological support - Encapsulation methods for targeted release in colon - Synbiotic combinations (probiotics + prebiotics + postbiotics) ## Market Position and Recognition - Recognized as a "High-Tech Enterprise" by Shanghai Municipality - Products published in journals such as Frontiers in Microbiology and Nutrients - Regular exhibitor at: - Hi China - CPhI Worldwide - Vitafoods Asia - Multiple client testimonials citing: - High CFU retention over shelf life - Fast formulation development for private labels - Scientific documentation for regulatory submissions Shanghai Unibio Lab Co., Ltd. is setting new benchmarks in microbiome health solutions with its clinically backed, technologically superior, and market-responsive probiotic innovations. As demand for gut and immune health surges globally, Unibio continues to be a preferred partner for science-based, high-performance microbiome ingredients.